Curated News
By: NewsRamp Editorial Staff
May 20, 2026
Cardio Diagnostics CEO Reveals AI-Powered Heart Disease Breakthroughs on Podcast
TLDR
- Cardio Diagnostics' AI platform and Medicare progress position it as a leader in precision cardiovascular medicine, offering a competitive edge in early detection.
- Using AI, epigenetics, and genetics, Cardio Diagnostics' integrated engine analyzes biomarkers to enable personalized prevention and detection of cardiovascular disease.
- Cardio Diagnostics aims to make cardiovascular care more accessible and precise, potentially saving lives through early detection and personalized treatment.
- CEO Dr. Meesha Dogan discussed Cardio Diagnostics' expansion into India and progress through the Medicare reimbursement process on the BioMedWire Podcast.
Impact - Why it Matters
This news matters because cardiovascular disease remains the leading cause of death globally. Cardio Diagnostics' precision medicine approach, using AI and epigenetics, could revolutionize early detection and prevention, potentially saving millions of lives. The company's progress in Medicare reimbursement and expansion into India signals growing accessibility to advanced diagnostics, which may lead to more personalized and effective treatments for patients worldwide.
Summary
In a recent episode of The BioMedWire Podcast, Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics Holdings (NASDAQ: CDIO), shared the company's vision to transform cardiovascular disease prevention and early detection through precision medicine. Leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine, Cardio Diagnostics aims to make cardiovascular care more accessible, personalized, and precise. Dr. Dogan highlighted the company's expansion into India through strategic partnerships with Aimil Ltd. and Dr. Lal PathLabs, which is set to broaden the reach of their innovative tests. Additionally, she provided an update on the Medicare reimbursement process, noting that CPT coding and payment steps have been completed, while coverage determination is still underway.
Cardio Diagnostics is at the forefront of integrating epigenetics, genetics, and AI to address the global burden of cardiovascular disease. The company's core technology analyzes genetic and epigenetic markers to provide individualized risk assessments and early detection, potentially saving lives by enabling timely interventions. During the podcast, Dr. Dogan emphasized the importance of these advancements in making cardiovascular care more proactive rather than reactive. The partnership with Aimil Ltd. and Dr. Lal PathLabs in India is a significant step toward global expansion, aiming to bring these cutting-edge solutions to a larger population.
BioMedWire, the platform hosting the podcast, is a specialized communications service within the Dynamic Brand Portfolio of IBN. It focuses on the latest developments in biotech, biomedical sciences, and life sciences. For investors and stakeholders, the latest news and updates relating to CDIO are available in the company’s newsroom. This podcast episode underscores Cardio Diagnostics' commitment to revolutionizing cardiovascular care through precision medicine and AI, with tangible progress in market expansion and regulatory milestones.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cardio Diagnostics CEO Reveals AI-Powered Heart Disease Breakthroughs on Podcast
